The proposal is put forward by three hypertension experts in a Viewpoint published early Online and in an upcoming edition of The Lancet. All three experts are attending this week’s International Society of Hypertension meeting in Berlin.
Systolic blood pressure (SBP) is the peak pressure in the arteries at the beginning of the heart’s pumping cycle, while diastolic blood pressure (DBP) is the lowest pressure in the rest phase of the cycle. Both are routinely measured in patients, to give a value of systolic over diastolic, eg. 120/80 mm Hg.
Bryan Williams, University of Leicester and Leicester Royal Infirmary, UK, Lars H. Lindholm, Umeå University Hospital, Sweden, and Peter Sever, International Centre for Circulatory Health, Imperial College London, UK, say that, because of aging populations, systolic hypertension (SH) is becoming much more common and important due to its high prevalence in patients over 50, compared with diastolic hypertension (DH).
SBP rises with age; but DBP only rises until age 50 years and falls thereafter, at a time when risk of cardiovascular disease begins to rise. Thus there is an increased prevalence of SH over age 50 years and an almost total disappearance of DH. The authors say: “Since more than 75% of people with hypertension are aged over 50 years, the burden of disease in mainly due to systolic pressure. The use of diastolic pressure for diagnosis and risk analysis in our ageing populations has thus become illogical.”
In order to simplify treatment strategies for physicians and policy makers, as well as to better focus the minds of drug innovators on the correct targets, the authors propose that, in patients over 50, only SBP needs to be measured, for four reasons. Firstly, SBP is more easily and accurately measured than DBP and is a better predictor of risk. Second, communication with patients would be much easier with just one number, ie, their SBP, since two different numbers leave many of them confused about which is of greater significance. Third, doctors themselves have received many conflicting messages about SBP and DBP, and many still use DBP to guide treatment decisions. This proposal would simplify things for them. And lastly, focussing a public-health campaign on a single number for people aged over 50 years has the potential to dramatically improve treatment outcomes for those with SH, and reduce the associated disease and death rates.
The risk of cardiovascular disease rises continuously as SBP increases from 115 mm Hg. Most international and national guidelines advocate a target of below 140 mm Hg, but there is a lack of evidence from prospective randomised clinical trials to define the best target for SBP treatment. The authors say: “Such trials are much needed and perhaps our call for a renewed focus on SBP will provide a catalyst for them to be designed.”
The authors acknowledge that for patients aged under 50 years, the scenario is different. In patients aged under 40 years, up to 40% of patients with hypertension have isolated DH, while between 40 and 50 years this figure is around a third. Thus for these patients, a continued emphasis on both SBP and DBP is appropriate. The authors say: “However, this much smaller group of patients should not dilute the key message regarding the overwhelming importance of systolic blood pressure for most patients with hypertension.” They add that focussing on SBP in these younger patients will almost always result in adequate control of DBP; yet if DBP is the sole target, many patients most at risk will be left with uncontrolled SPB.
They conclude: “We believe that systolic blood pressure should become the sole defining feature of hypertension and key treatment target for people over age 50 years...[this] will simplify the message for practitioners and for patients, will improve awareness and understanding of treatment objectives, and will ultimately lead to more effective treatment of high blood pressure. Such an initiative would have major public-health implications for the prevention of blood-pressure related cardiovascular disease.”
Ather Mirza | alfa
Spread of deadly eye cancer halted in cells and animals
13.11.2018 | Johns Hopkins Medicine
Breakthrough in understanding how deadly pneumococcus avoids immune defenses
13.11.2018 | University of Liverpool
Biochips have been developed at TU Wien (Vienna), on which tissue can be produced and examined. This allows supplying the tissue with different substances in a very controlled way.
Cultivating human cells in the Petri dish is not a big challenge today. Producing artificial tissue, however, permeated by fine blood vessels, is a much more...
Faster and secure data communication: This is the goal of a new joint project involving physicists from the University of Würzburg. The German Federal Ministry of Education and Research funds the project with 14.8 million euro.
In our digital world data security and secure communication are becoming more and more important. Quantum communication is a promising approach to achieve...
On Saturday, 10 November 2018, the research icebreaker Polarstern will leave its homeport of Bremerhaven, bound for Cape Town, South Africa.
When choosing materials to make something, trade-offs need to be made between a host of properties, such as thickness, stiffness and weight. Depending on the application in question, finding just the right balance is the difference between success and failure
Now, a team of Penn Engineers has demonstrated a new material they call "nanocardboard," an ultrathin equivalent of corrugated paper cardboard. A square...
Physicists at ETH Zurich demonstrate how errors that occur during the manipulation of quantum system can be monitored and corrected on the fly
The field of quantum computation has seen tremendous progress in recent years. Bit by bit, quantum devices start to challenge conventional computers, at least...
09.11.2018 | Event News
06.11.2018 | Event News
23.10.2018 | Event News
13.11.2018 | Life Sciences
13.11.2018 | Life Sciences
13.11.2018 | Awards Funding